NEW YORK, Dec. 16, 2016 /PRNewswire/ -- Flat-Rate Access to R&D Database & Reports from La Merie Publishing
- R&D Drug Pipeline Database: 1-Year Subscription
- Flat-Rate Subscription to La Merie Publishing Reports & News Services
A one-year subscription to this product provides 24/7 online access to both services from La Merie Publishing with a 30% discount on the list prices for all license types. Internet access is the only prerequisite for this service.
Upon purchase of the Flat-Rate Access to R&D Database & Reports from La Merie Publishing, credentials to access the database and a dedicated server account with the report archive will be provided by e-mail. New issues of R&D Pipeline News and the R&D and Business Tracking Services will be delivered by e-mail, old issues are archived in the dedicated server account.
1) Flat-Rate Subscription to La Merie Publishing Reports & News Services
A one-year subscription to this service provides access to
- all existing La Merie Publishing reports on stock and listed online in the store;
- all new reports released by La Merie Publishing during the term of the subscription;
- 12 (monthly) issues of three different R&D and Business Tracking services;
- 50 (weekly) issues of R&D Pipeline News
Among La Merie Publishing reports are:
- Competitor Analysis reports in tabular presentation format;
- Brief Reports; and
- Full Reports.
A full listing of existing reports can be found in the online store. Publishing activities include updates of existing reports as well as release of new reports.
Among La Merie Publishings News & Information Services are:
- R&D and Business Tracker for TCR & CAR T-Cells and NK Cells;
- R&D and Business Tracker for Bispecific Antibodies;
- R&D and Business Tracker for Antibody-Drug Conjugates;
- R&D Pipeline News - Technology Edition;
- R&D Pipeline News - Therapeutic Area Edition.
After purchase of the Flat-Rate Subscription to La Merie Publishing Reports & News Services, credentials to access a dedicated server account with the report archive will be provided by e-mail. New issues of R&D Pipeline News and the R&D and Business Tracking Services will be delivered by e-mail, old issues are archived in the dedicated server account.
Coverage of La Merie Publishing reports:
La Merie Publishing has a special focus on biologics including, but not limited to
Bispecific antibodies including T-cell or NK cell redireting antibodies
CAR & TCR engineered T-cells and NK cells;
Biosimilar antibodies and proteins
Therapeutic and prophylactic vaccines;
Reports of the Competitor Analysis Series deliver NO-FRILLS, but concise information about the pipeline of R&D projects for targets, diseases and technologies provided in a tabular format and fully referenced.
Full Reports and Brief Reports provide in-depth description and analysis of targets, pipelines, companies and technologies.
Examples of Full Reports as of November 2016 are
TCR & CAR Engineered T-Cell and NK Cell Therapeutics 2016: Convergence of technologies opens business opportunities beyond CD19 CARTs
T-Cell Redirecting Bispecific Antibodies 2016: A competitive landscape analysis of stakeholders, technologies, pipelines and deals
Examples of Brief Reports as of November 2016 are
CD22: a suitable antigen for targeted payload delivery by immunotherapeutics
CD123: a paradigmatic target for immunotherapeutic treatment modalities
RORgamma Modulators 2016: A comparative analysis of the landscape of RORgamma antagonists and agonists
Examples of Competitor Analysis Reports as of November 2016 are:
Biosimilar and Biosuperior Therapeutic Antibodies
PD-1 and PD-L1 Immune Checkpoint Inhibitors 2016
Bispecific Antibodies for Cancer, Inflammatory & Other Diseases
PTH Receptor Agonists 2016 and Teriparatide Biosimilars and Biosuperiors
Examples of Vaccine Reports
Clostridium Difficile Vaccines and Therapeutics 2016
Flavivirus Vaccines: Zika, Dengue, Chikungunya, West Nile, Yellow Fever, Japanese Encephalitis & Tick-Borne Encephalitis Virus Vaccines
Examples of Peptide Reports
R&D Drug Pipeline Database: 1-Year Subscription
Subscription to La Merie Publishing's proprietary R&D Drug Pieline Database provides 24/7 online access to information about more than 21,000 project entries (files) for therapeutic drugs on the market and on investigational drug candidates in research & development.
Pre-established and free search functions allow to identify molecules according to their
Product category (NCE, antibodies, proteins, DNA, RNA, cells, vaccines, peptides)
Technology (e.g. antibody-drug conjugate, bispecific antibody)
Target (e.g. Her2, Amyloid beta, TNF, PD-1/PD-L1)
Pipelines (selected by target, therapeutic area, company, technology)
Sales (for marketed antibodies, peptides and proteins)
R&D Phase (clinical phases, market, preclinical)
Therapeutic Area (e.g. infectious, oncology, gastrointestinal)
Drug Code/Name (for individual molecules)
Each project is specified for its Target, Therapeutic Area and R&D Phase. Use of the R&D Drug Pipeline Database is intuitive. Data sets of interest can be printed and exported as reports in Excel or Word format. Projects are being updated continuously. The R&D history of each project with online references of information sources can be viewed and printed. Sales figures of major therapeutic antibodies, proteins and peptides on the market are provided.
An advanced search function allows to combine search parameters. A scroll down menu for predefined targets and technologies conveniently selects projects of interest. By clicking on column heads of the project list, projects can be arranged in ascending or descending alphabetical or numerical order, e.g. for phase or company name.
Special Focus of the Database:
Prerequisite: Internet access
Purchase of the subscription provides a 1-year online access to the data of the R&D Drug Pipeline Database. Credentials to access the database will be sent by e-mail within 24 hours after purchase.
Benefits from the R&D Drug Pipeline Database:
24/7 online access
Designed for structured searches
Focused on targets, product categories and R&D phases
Ideal for competitor analysis (companies, targets, product categories)
Cost-effective and rapid solution for benchmarking
Identification of licensing candidates
Project listing in a tabular format:
Target / Mechanism of Action
Class of Compound
Cardiovascular, blood & acute care
Genitourinary, gynecology & renal
Infectious & toxicology
Metabolism & endocrine
Neurology & psychiatry
Ophthalmolgoy & otorhinolaryngology
Orthopedics, dental, anesthesia & surgery
Pulmonary & respiratory
Rheumatoid & autoimmune
Examples of Predefined Targets of the Scroll Down Menu:
Antibody-Drug Conjugates (ADC)
Sales of Antibodies & Proteins 2015
CAR & TCR Engineered T-Cells and NK Cells
Adalimumab (Humira) Biosimilars
Amyloid beta-Targeted Antibodies
Peptide Sales 2015
PD-1 & PD-L1 Immune Checkpoint Inhibitors
Zika Virus Vaccines
Human Papilloma Virus (HPV) Vaccines & Therapeutics
G-CSF & GM-CSF
Immune Checkpoint Modulators
Examples of Predefined Technologies of the Scroll Down Menu:
Transgenic XenoMouse Antibodies
T-Cell Redirecting Bispecific Antibodies
ADC - Pyrrolobenzodiazepine (PBD)
Oligo- and Polyclonal Antibodies
Read the full report: http://www.reportlinker.com/p04339717-summary/view-report.html
ReportLinker is an award-winning market research solution. Reportlinker finds and organizes the latest industry data so you get all the market research you need - instantly, in one place.
Contact Clare: email@example.com
Intl: +1 339-368-6001
To view the original version on PR Newswire, visit:http://www.prnewswire.com/news-releases/flat-rate-access-to-rd-database--reports-from-la-merie-publishing-300380145.html